Trial Profile
KRP-AM1977X Phase II Clinical Study -To assess efficacy, safety and pharmacokinetics of KRP-AM1977X in the patients with community acquired pneumonia
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Dec 2021
Price :
$35
*
At a glance
- Drugs Lascufloxacin (Primary)
- Indications Community-acquired pneumonia
- Focus Therapeutic Use
- Sponsors Kyorin Pharmaceutical
- 25 Apr 2017 Results assessing the safety and efficacy of oral lascufloxacin in Japanese patients with community-acquired pneumonia, presented at the 27th European Congress of Clinical Microbiology and Infectious Diseases.
- 14 Mar 2016 New trial record